M&A Deal Summary |
|
---|---|
Date | 2012-01-31 |
Target | Navilyst Medical |
Sector | Healthcare Services |
Buyer(s) | AngioDynamics |
Sellers(s) | Avista Healthcare Partners |
Deal Type | Add-on Acquisition |
Deal Value | 372M USD |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1988 |
Sector | Medical Products |
Employees | 760 |
Revenue | 339M USD (2023) |
AngioDynamics is a provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics was incorporated in 1988 and is based in Latham, New York.
DEAL STATS | # |
---|---|
Overall | 5 of 9 |
Sector (Healthcare Services) | 1 of 1 |
Type (Add-on Acquisition) | 4 of 8 |
Country (United States) | 5 of 8 |
Year (2012) | 1 of 2 |
Size (of disclosed) | 1 of 4 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2009-01-12 |
FlowMedica
Fremont, California, United States FlowMedica, Inc. manufactures intravascular systems for implementing Targeted Renal Therapy. |
Buy | $2M |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2012-10-08 |
Vortex Medical
Norwell, Massachusetts, United States Vortex Medical, Inc. is a medical device company focused on the design, development and commercialization of novel endomechanical devices for the endovascular market. |
Buy | - |
Category | Private Equity Firm |
---|---|
Founded | 2005 |
PE ASSETS | 8.0B USD |
Size | Mega |
Type | Sector Focused |
Avista Capital Partners is a private investment firm formed by a group of professionals with roots from DLJ Merchant Banking Partners. Avista makes controlling and minority investments in US based energy, healthcare, and media companies with revenues greater than $25 million. Typical transactions include leverage buyouts, build-ups, and growth capital financings. Avista Capital was formed in 2005 and is based in New York City with an additional office in Houston, Texas.
DEAL STATS | # |
---|---|
Overall | 9 of 30 |
Sector (Healthcare Services) | 2 of 3 |
Type (Add-on Acquisition) | 5 of 15 |
Country (United States) | 7 of 24 |
Year (2012) | 2 of 4 |
Size (of disclosed) | 8 of 11 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2012-01-31 |
BioReliance
Rockville, Maryland, United States BioReliance provides critical services that include biologic, specialized toxicology and animal health testing to pharmaceutical, biopharmaceutical, diagnostics, and other life science customers worldwide. |
Sell | $350M |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2012-05-02 |
Fougera Pharmaceuticals
Melville, New York, United States Fougera Pharmaceuticals Inc. operates two primary divisions in the US focused on specialty pharmaceuticals in dermatology: Fougera, its generic dermatology medicines business, and PharmaDerm, its branded dermatology business. Founded in 1849, the Fougera division is the leading manufacturer and distributor of a wide range of topical products. The PharmaDerm division is dedicated to developing and commercializing novel prescription products to treat diseases and conditions of the skin – the largest organ of the human body. |
Sell | $1.5B |